INBX
Inhibrx Biosciences, Inc.
100.40$
+0.1%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 254.9% | 304.0% | 389.2% | 526.9% | 573.8% | 37.7% | 5,026.7% | 66.2% | 1,142.5% | 191.0% | |
| -154.9% | -204.0% | -289.2% | -426.9% | -473.8% | 62.3% | -4,926.7% | 33.8% | -1,042.5% | -91.0% | |
| 254.9% | 304.0% | 389.2% | 526.9% | 573.8% | 1,002.7% | 5,026.7% | 10,591.6% | 101,871.5% | 8,694.5% | |
| 27.3% | 31.1% | 54.1% | 99.2% | 53.4% | 173.4% | 963.6% | 1,632.3% | 63,952.5% | 1,792.1% | |
| 278.4% | 329.9% | 53.4% | 110.9% | 626.6% | 1,138.3% | 963.6% | 12,212.8% | 164,681.5% | 10,295.5% | |
| -182.2% | -235.1% | -343.4% | -450.4% | -526.6% | -1,076.1% | -5,890.4% | -12,178.9% | -165,724.0% | -10,386.5% | |
| – | 25.3% | 17.2% | 62.9% | 84.4% | 73.2% | 734.8% | 1,768.9% | 6,745.5% | 938.2% | |
| -193.3% | -260.2% | -359.8% | -555.4% | -590.5% | -1,147.6% | -6,625.1% | -13,318.0% | 843,787.0% | -10,773.3% | |
| -69.2% | 3.0% | 1.1% | 9.9% | 0.0% | 0.0% | 0.1% | 0.2% | 1.0% | 0.2% | |
| -124.0% | -231.7% | -362.6% | -565.3% | -594.3% | -1,147.6% | -6,625.3% | -13,408.9% | 843,786.0% | -10,773.5% | |
| -178.4% | -230.1% | -334.7% | -437.6% | -518.6% | -1,074.4% | -5,739.8% | -11,482.9% | 851,675.0% | -9,644.2% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.